National Bank of Canada’s Amneal Pharmaceuticals AMRX Stock Holding History

National Bank of Canada’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.12K	Sell	654 -215	-25%	-$2.89K	﹤0.01%	2384
2025 Q4	$10.9K	Sell	869 -4	-0.5%	-$46	﹤0.01%	2292
2025 Q3	$8.74K	Buy	873 +312	+56%	+$2.8K	﹤0.01%	2354
2025 Q2	$4.53K	Sell	561 -219	-28%	-$1.65K	﹤0.01%	2505
2025 Q1	$6.53K	Buy	+780	New	+$6.51K	﹤0.01%	2325
2024 Q4	–	Sell	-2	Closed	-$17	–	2930
2024 Q3	$17	Buy	+2	New	+$16	﹤0.01%	2657
2024 Q1	–	Sell	-1,800	Closed	-$10.7K	–	2724
2023 Q4	$10.7K	Hold	1,800	–	–	﹤0.01%	2154
2023 Q3	$7.69K	Hold	1,800	–	–	﹤0.01%	2262
2023 Q2	$5.58K	Hold	1,800	–	–	﹤0.01%	2315
2023 Q1	$2.5K	Hold	1,800	–	–	﹤0.01%	2407
2022 Q4	$3.56K	Hold	1,800	–	–	﹤0.01%	2391
2022 Q3	$4K	Hold	1,800	–	–	﹤0.01%	2365
2022 Q2	$6K	Hold	1,800	–	–	﹤0.01%	2369
2022 Q1	$7K	Hold	1,800	–	–	﹤0.01%	2459
2021 Q4	$9K	Buy	+1,800	New	+$8.97K	﹤0.01%	2376

Other funds holding AMRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

National Bank of Canada's AMRX Position: Q1 2026 in Review

National Bank of Canada reduced its Amneal Pharmaceuticals (AMRX) stake by 25% in Q1 2026, selling an estimated $2.89K and leaving 654 shares worth $8.12K. The position accounts for ﹤0.01% of the portfolio, ranked #2384.

National Bank of Canada first reported a position in AMRX in Q4 2021 and has held it in 15 quarters since. The position peaked at $10.9K in Q4 2025. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

National Bank of Canada held 654 shares of Amneal Pharmaceuticals worth $8.12K as of Q1 2026.
National Bank of Canada sold 215 Amneal Pharmaceuticals shares in Q1 2026, an estimated $2.89K.
Amneal Pharmaceuticals made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2384 holding.
National Bank of Canada first reported a position in Amneal Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
National Bank of Canada's Amneal Pharmaceuticals position peaked at $10.9K in Q4 2025.
316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.